BioVie (NASDAQ: BIVI): Poised for Significant Catalysts in 2023

BioVie is poised for significant catalysts in 2023, including data read out from its
Alzheimer’s Phase 3 trial, expected in Q3 2023, as well as interim data read outs
from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. Learn more at: https://www.redchip.com/stocks/bivi

0:00 - Start
0:29 - Company Overview
3:35 - Market Potential
5:07 - Additional Late-stage Programs
7:15 - Upcoming Catalysts
8:00 - Management Team
9:27 - Value Proposition